Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Combined Synopsis/Solicitation opportunity from Department Of Energy was posted on May 15, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Emerging Technologies Opportunity Program (ETOP) 2026 - Development of an automated system for plant tissue culture and transformation

Closed
PTC-ETOP-2026Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Grant
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)This contract opportunity from the National Institutes of Health under the Department of Health and Human Services aims to support the development of safe, effective, and non-addictive small molecule and biologic therapeutics for pain treatment. It focuses on accelerating early-stage therapeutic candidates through preclinical optimization to readiness for Phase II clinical trials. Eligible applicants must present a promising lead candidate with strong biological justification and established assays to guide optimization. The funded activities include lead optimization, early development, IND-enabling studies, biomarker development, submission of an Investigational New Drug application, and Phase I clinical testing. The program is structured as a milestone-driven, phased cooperative agreement with active NIH involvement in project planning and monitoring. The solicitation is identified as RFA-NS-27-007, titled HEAL Initiative: Non-addictive Analgesic Therapeutics Development, with clinical trials optional. The solicitation was posted on June 16, 2026, and applicants must respond by February 20, 2029. This federal contract emphasizes collaborative advancement of innovative pain therapeutics while ensuring rigorous oversight from NIH program staff throughout the project lifecycle.
National Institutes Of Health

POSTED

about 23 hours ago

DEADLINE

in over 2 years
NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.
Triad - DOE Contractor

POSTED

2 days ago

DEADLINE

in 6 months
NAICS: 541714
New
Federal
Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

Show more

The University of California, on behalf of Lawrence Berkeley National Laboratory (LBNL), has issued Request for Proposal (RFP) No. PTC-ETOP-2026 seeking the development of an automated system for plant tissue culture and transformation. This contract opportunity targets the automation of selecting embryogenic portions of plant calluses, transferring them to fresh media, and monitoring their growth toward scalability targets aligned with Department of Energy (DOE) biomass crops. The solicitation invites offerors to submit proposals by June 1, 2026, with a structured evaluation process emphasizing technical capabilities, scalability, automation levels, transferability of technology to the Joint Genome Institute (JGI), and compliance with detailed business and financial requirements. The estimated contract ceiling is $2 million, and proposals must include multiple documentation elements such as representations and certifications, cost proposals in Excel format, and required attestations on accounting and timekeeping systems. Proposals will be evaluated on a trade-off basis considering technical merit, business volume factors, compliance with subcontract terms, and cost realism rather than lowest price. Mandatory minimum technical criteria include demonstrating applicability to DOE’s biomass crops, throughput scalability of at least 10,000 calluses per day, and achieving regeneration rates of 75% or higher. Desired features focus on achieving 80% or more automation of workflow steps and ease of technology transfer with limited required expertise. Business factors require offerors to accept the Sample Subcontract terms without unmitigated exceptions or provide detailed risk justifications. Additional contract requirements emphasize sustainability compliance—including prohibitions on foam and single-use plastics in packaging—environmentally responsible waste management, and DOE barcode labeling for government-furnished property. Invoicing procedures are electronic via email with specific format restrictions, and no explicit government contact roles or detailed FAR clause listings have been provided, though key clauses like Equal Opportunity and Affirmative Action are referenced. Overall, this solicitation mandates rigorous technical, financial, and regulatory standards aimed at fostering innovative, scalable automation technologies for plant transformation within a DOE research context.

General Info

UC Berkeley seeks automated plant tissue culture system with DOE scalability, $2M ceiling, proposals due June 2026.

Agency

Department Of Energy → Berkeley National Labor - DOE Contractor

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Berkeley, CA, 94720, USA

Set-Aside

NONE

Documents

(8)

Preaward Survey of Prospective Subcontractor's Cost Accounting System

DOCXpreaward-survey

RFP PTC-ETOP-2026 Emerging Technologies Opportunity Program 2026

DOCXrfp

Subcontract No. XXXXXXX for Automated Callus Research System Development

PDFcontract-document

Q&A for RFP No. PTC-ETOP-2026

PDFq-and-a

Representation and Certification Form for Offeror Proposal

DOCXrep-certification

5.+Sample+Cost+Proposal.xlsx

XLSX

4.+Insurance+Certificate+Instructions.pdf

PDF

6.+Small+Business+Subcontracting+Plan.docx

DOCX

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Combined Synopsis

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Energy → Berkeley National Labor - DOE Contractor
Contacts1 person available
OfficeBerkeley, CA, 94720, USA
Organization / Agency
Department Of Energy → Berkeley National Labor - DOE Contractor
Office AddressBerkeley, CA, 94720, USA

Full Description

Show more

This RFP is hereby modified as of 5/15/26 to add the attached Question & Answer document. All others terms and conditions of this RFP remain the same.


__________________________________________________________


Dear Prospective Offeror,


The University of California, on behalf of the Lawrence Berkeley National Laboratory (LBNL), would like to invite you to participate in Request for Proposal (RFP) No. PTC-ETOP-2026 for development of an automated system for plant tissue culture and transformation. 



The RFP and associated documents (listed below) are attached hereto:


0.            RFP and Proposal Preparation Instructions


1.            Rep Cert Form (required with submission)


2.            Preaward Survey of Prospective Subcontractor’s Accounting System (required with submission)


3.            Sample Subcontract


4.            Insurance Certificate Instructions


5.           Sample Cost Proposal


6.           Small Business Subcontracting Plan



Timeline of Events:


RFP Release – 04/29/2026


Offeror Questions Due – 05/14/2026


Proposals Due – 06/01/2026, no later than 12 p.m. PDT


Oral Presentations – TBD